The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 02, 2010

Filed:

Mar. 23, 2005
Applicants:

Wesley Blackaby, Harlow, GB;

Mark E. Duggan, Wellesley, MA (US);

David Hallett, Harlow, GB;

George D. Hartman, Landsdale, PA (US);

Andrew S. Jennings, Harlow, GB;

William H. Leister, Quakertown, PA (US);

Richard T. Lewis, Harlow, GB;

Craig W. Lindsley, Schwenksville, PA (US);

Elizabeth Naylor, Harlow, GB;

Leslie J. Street, Harlow, GB;

Yi Wang, North Wales, PA (US);

David D. Wisnoski, Quakertown, PA (US);

Scott E. Wolkenberg, Jenkintown, PA (US);

Zhijian Zhao, Wilimington, DE (US);

Inventors:

Wesley Blackaby, Harlow, GB;

Mark E. Duggan, Wellesley, MA (US);

David Hallett, Harlow, GB;

George D. Hartman, Landsdale, PA (US);

Andrew S. Jennings, Harlow, GB;

William H. Leister, Quakertown, PA (US);

Richard T. Lewis, Harlow, GB;

Craig W. Lindsley, Schwenksville, PA (US);

Elizabeth Naylor, Harlow, GB;

Leslie J. Street, Harlow, GB;

Yi Wang, North Wales, PA (US);

David D. Wisnoski, Quakertown, PA (US);

Scott E. Wolkenberg, Jenkintown, PA (US);

Zhijian Zhao, Wilimington, DE (US);

Assignees:

Merck Sharp & Dohme Limited, Hertfordshire, GB;

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/435 (2006.01); A61K 31/445 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.


Find Patent Forward Citations

Loading…